Catalyst Crew Technologies Seeks FINRA Approval for Name Change to LataMed AI Corp.

Catalyst Crew Technologies Corp. (OTC: CCTC) announced it has submitted a corporate action request to the Financial Industry Regulatory Authority (FINRA) seeking approval for a proposed corporate name change to LataMed AI Corp. and a corresponding change to the Company's trading symbol. The proposed name change is intended to better reflect the Company's current strategic direction following its transition toward artificial intelligence-enabled healthcare technology, including healthcare analytics and technology-enabled healthcare services infrastructure, with an initial strategic focus on Latin America.

The proposed corporate action was approved by the Company's Board of Directors and by written consent of the Company's majority shareholder in accordance with Nevada law. The Company noted that the proposed corporate action does not involve any reverse stock split, forward stock split, recapitalization, change to authorized capital, or other modification to the Company's capital structure. The Company's issued and outstanding share count will remain unchanged in connection with the proposed name and symbol change. The name change and corresponding trading symbol change will not affect shareholders' ownership interests in the Company and no action will be required by existing shareholders.

Upon FINRA approval, the Company intends to file a Certificate of Amendment with the Nevada Secretary of State to effect the corporate name change. The proposed name change and symbol change would become effective upon completion of the required corporate filings and publication by FINRA on the Daily List. "There is no change to the Company's capital structure as part of this process," said Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp. "This proposed name change is intended to better align the Company's public identity with its healthcare technology strategy and long-term market focus." No assurance can be given that FINRA will approve the proposed name change, the requested new trading symbol, or the timing of any such approval.

For more information, please visit https://catalystcrewai.com or review the Company's filings with the U.S. Securities and Exchange Commission at https://www.sec.gov. The Company is an artificial intelligence-driven healthcare technology company focused on developing scalable digital health solutions for emerging markets, with an initial emphasis on Latin America. The Company is actively executing its strategic transition into AI-enabled healthcare and pursuing opportunities across telehealth infrastructure, remote patient monitoring, healthcare data analytics, and integrated digital care platforms designed to improve access, efficiency, and care coordination.